Ryan Deschner
Stock Analyst at Raymond James
(4.71)
# 721
Out of 4,396 analysts
59
Total ratings
64.7%
Success rate
36.5%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ryan Deschner
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LQDA Liquidia | Maintained: Buy | n/a | $64.01 | - | 12 | Jun 4, 2026 | |
| VERA Vera Therapeutics | Maintained: Buy | n/a | $31.81 | - | 5 | Jun 2, 2026 | |
| IFRX InflaRx | Maintained: Buy | $9 | $1.66 | +442.17% | 4 | May 13, 2026 | |
| MIRM Mirum Pharmaceuticals | Maintained: Buy | $110 → $165 | $95.48 | +72.81% | 4 | May 7, 2026 | |
| DNTH Dianthus Therapeutics | Maintained: Buy | $123 → $125 | $84.57 | +47.81% | 4 | May 6, 2026 | |
| KRRO Korro Bio | Upgraded: Buy | $23 | $10.94 | +110.24% | 2 | Mar 13, 2026 | |
| SPRY ARS Pharmaceuticals | Maintained: Buy | n/a | $9.41 | - | 11 | Jan 9, 2026 | |
| PVLA Palvella Therapeutics | Upgraded: Buy | $54 → $143 | $104.37 | +37.01% | 2 | Nov 19, 2025 | |
| TVRD Tvardi Therapeutics | Downgraded: Hold | n/a | $2.78 | - | 4 | Oct 14, 2025 | |
| VKTX Viking Therapeutics | Reiterated: Buy | $122 | $29.23 | +317.38% | 1 | Aug 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $29 → $27 | $13.59 | +98.75% | 5 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $11 → $12 | $5.60 | +114.29% | 4 | Aug 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $14 | $1.47 | n/a | 1 | May 9, 2025 |
Liquidia
Jun 4, 2026
Maintained: Buy
Price Target: n/a
Current: $64.01
Upside: -
Vera Therapeutics
Jun 2, 2026
Maintained: Buy
Price Target: n/a
Current: $31.81
Upside: -
InflaRx
May 13, 2026
Maintained: Buy
Price Target: $9
Current: $1.66
Upside: +442.17%
Mirum Pharmaceuticals
May 7, 2026
Maintained: Buy
Price Target: $110 → $165
Current: $95.48
Upside: +72.81%
Dianthus Therapeutics
May 6, 2026
Maintained: Buy
Price Target: $123 → $125
Current: $84.57
Upside: +47.81%
Korro Bio
Mar 13, 2026
Upgraded: Buy
Price Target: $23
Current: $10.94
Upside: +110.24%
ARS Pharmaceuticals
Jan 9, 2026
Maintained: Buy
Price Target: n/a
Current: $9.41
Upside: -
Palvella Therapeutics
Nov 19, 2025
Upgraded: Buy
Price Target: $54 → $143
Current: $104.37
Upside: +37.01%
Tvardi Therapeutics
Oct 14, 2025
Downgraded: Hold
Price Target: n/a
Current: $2.78
Upside: -
Viking Therapeutics
Aug 19, 2025
Reiterated: Buy
Price Target: $122
Current: $29.23
Upside: +317.38%
Aug 8, 2025
Maintained: Buy
Price Target: $29 → $27
Current: $13.59
Upside: +98.75%
Aug 5, 2025
Maintained: Buy
Price Target: $11 → $12
Current: $5.60
Upside: +114.29%
May 9, 2025
Reiterated: Buy
Price Target: $14
Current: $1.47
Upside: n/a